574 related articles for article (PubMed ID: 26283155)
1. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN
Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155
[TBL] [Abstract][Full Text] [Related]
2. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer.
Moura V; Lacerda M; Figueiredo P; Corvo ML; Cruz ME; Soares R; de Lima MC; Simões S; Moreira JN
Breast Cancer Res Treat; 2012 May; 133(1):61-73. PubMed ID: 21805188
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
Fonseca NA; Gomes-da-Silva LC; Moura V; Simões S; Moreira JN
J Control Release; 2014 Dec; 196():122-31. PubMed ID: 25305563
[TBL] [Abstract][Full Text] [Related]
4. Nucleolin is expressed in patient-derived samples and glioblastoma cells, enabling improved intracellular drug delivery and cytotoxicity.
Balça-Silva J; do Carmo A; Tão H; Rebelo O; Barbosa M; Moura-Neto V; Sarmento-Ribeiro AB; Lopes MC; Moreira JN
Exp Cell Res; 2018 Sep; 370(1):68-77. PubMed ID: 29902537
[TBL] [Abstract][Full Text] [Related]
5. The cancer stem cell phenotype as a determinant factor of the heterotypic nature of breast tumors.
Fonseca NA; Cruz AF; Moura V; Simões S; Moreira JN
Crit Rev Oncol Hematol; 2017 May; 113():111-121. PubMed ID: 28427501
[TBL] [Abstract][Full Text] [Related]
6. Co-Eradication of Breast Cancer Cells and Cancer Stem Cells by Cross-Linked Multilamellar Liposomes Enhances Tumor Treatment.
Kim YJ; Liu Y; Li S; Rohrs J; Zhang R; Zhang X; Wang P
Mol Pharm; 2015 Aug; 12(8):2811-22. PubMed ID: 26098197
[TBL] [Abstract][Full Text] [Related]
7. Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity.
Bamodu OA; Huang WC; Tzeng DT; Wu A; Wang LS; Yeh CT; Chao TY
Cancer Lett; 2015 Aug; 364(2):125-34. PubMed ID: 25976769
[TBL] [Abstract][Full Text] [Related]
8. CRYβB2 enhances tumorigenesis through upregulation of nucleolin in triple negative breast cancer.
Yan Y; Narayan A; Cho S; Cheng Z; Liu JO; Zhu H; Wang G; Wharram B; Lisok A; Brummet M; Saeki H; Huang T; Gabrielson K; Gabrielson E; Cope L; Kanaan YM; Afsari A; Naab T; Yfantis HG; Ambs S; Pomper MG; Sukumar S; Merino VF
Oncogene; 2021 Sep; 40(38):5752-5763. PubMed ID: 34341513
[TBL] [Abstract][Full Text] [Related]
9. Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment.
Gomes-da-Silva LC; Santos AO; Bimbo LM; Moura V; Ramalho JS; Pedroso de Lima MC; Simões S; Moreira JN
Int J Pharm; 2012 Sep; 434(1-2):9-19. PubMed ID: 22617794
[TBL] [Abstract][Full Text] [Related]
10. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
[TBL] [Abstract][Full Text] [Related]
11. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
[TBL] [Abstract][Full Text] [Related]
13. Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells.
Ke XY; Lin Ng VW; Gao SJ; Tong YW; Hedrick JL; Yang YY
Biomaterials; 2014 Jan; 35(3):1096-108. PubMed ID: 24183698
[TBL] [Abstract][Full Text] [Related]
14. p38γ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion.
Qi X; Yin N; Ma S; Lepp A; Tang J; Jing W; Johnson B; Dwinell MB; Chitambar CR; Chen G
Stem Cells; 2015 Sep; 33(9):2738-47. PubMed ID: 26077647
[TBL] [Abstract][Full Text] [Related]
15. Standardized Extract from Caesalpinia spinosa is Cytotoxic Over Cancer Stem Cells and Enhance Anticancer Activity of Doxorubicin.
Sandoval TA; Urueña CP; Llano M; Gómez-Cadena A; Hernández JF; Sequeda LG; Loaiza AE; Barreto A; Li S; Fiorentino S
Am J Chin Med; 2016; 44(8):1693-1717. PubMed ID: 27852125
[TBL] [Abstract][Full Text] [Related]
16. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.
Xu X; Zhang L; He X; Zhang P; Sun C; Xu X; Lu Y; Li F
Biochem Biophys Res Commun; 2018 Jul; 502(1):160-165. PubMed ID: 29792857
[TBL] [Abstract][Full Text] [Related]
17. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
18. Click conjugation of peptide to hydrogel nanoparticles for tumor-targeted drug delivery.
Qin M; Zong H; Kopelman R
Biomacromolecules; 2014 Oct; 15(10):3728-34. PubMed ID: 25162488
[TBL] [Abstract][Full Text] [Related]
19. Modelling the impact of nucleolin expression level on the activity of F3 peptide-targeted pH-sensitive pegylated liposomes containing doxorubicin.
Lopes R; Shi K; Fonseca NA; Gama A; Ramalho JS; Almeida L; Moura V; Simões S; Tidor B; Moreira JN
Drug Deliv Transl Res; 2022 Mar; 12(3):629-646. PubMed ID: 33860446
[TBL] [Abstract][Full Text] [Related]
20. The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer.
Doherty MR; Parvani JG; Tamagno I; Junk DJ; Bryson BL; Cheon HJ; Stark GR; Jackson MW
Breast Cancer Res; 2019 Apr; 21(1):54. PubMed ID: 31036052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
